机构：[1]Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China[2]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept Comprehens Oncol, Beijing, Peoples R China[3]Shandong Canc Hosp & Inst, Dept Resp Med, Beijing, Peoples R China[4]Shandong First Med Univ, Beijing, Peoples R China[5]Shandong Acad Med Sci, Beijing, Peoples R China[6]Capital Med Univ, Beijing Tongren Hosp, Ctr Canc, Beijing, Peoples R China首都医科大学附属北京同仁医院首都医科大学附属同仁医院
第一作者机构：[1]Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Dong Y.,Xu H.,Yang G.,et al.Dynamic profiling of ctDNA in HER2-alterated advanced NSCLC treated with pyrotinib and apatinib: Exploratory biomarker analysis from a phase II trial[J].ANNALS OF ONCOLOGY.2024,35:S255-S255.doi:10.1016/j.annonc.2024.08.110.
APA：
Dong, Y.,Xu, H.,Yang, G.,Yang, Y.,Zhang, S.&Wang, Y..(2024).Dynamic profiling of ctDNA in HER2-alterated advanced NSCLC treated with pyrotinib and apatinib: Exploratory biomarker analysis from a phase II trial.ANNALS OF ONCOLOGY,35,
MLA：
Dong, Y.,et al."Dynamic profiling of ctDNA in HER2-alterated advanced NSCLC treated with pyrotinib and apatinib: Exploratory biomarker analysis from a phase II trial".ANNALS OF ONCOLOGY 35.(2024):S255-S255
医学